# A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer

> **NCT00649090** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 1549 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT00649090
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 1549 (ACTUAL)
- **Last updated:** 2008-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649090, "A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00649090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*